SCD and neoplasm: An inhibition of stearoyl-CoA desaturase (SCD) through various approaches, including siRNAs and small-molecule inhibitors, has demonstrated efficacy in reducing tumour growth and metastasis across a spectrum of cancer types such as endometrial, bladder, thyroid, colon, glioblastoma, prostate, and lung cancers [81,82].